Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
21/04/2026 13:50
Enlivex Ltd ENLV.TA: ENLIVEX ANNOUNCES SECOND REGULATORY APPROVAL FOR PHASE 2B TRIAL OF ALLOCETRA IN AGE-RELATED PRIMARY MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS ENLIVEX LTD - PHASE 2B TRIAL OF ALLOCETRA TO ENROLL PATIENTS IN US, DENMARK, AND POLAND Source text: ID:nGNX93Pc89 Further company coverage: ENLV.TA
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment